Status:

COMPLETED

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

Lead Sponsor:

Richard H. Haas

Collaborating Sponsors:

Thrasher Research Fund

Conditions:

Seizures

Disorder of Fetus or Newborn

Eligibility:

All Genders

1-14 years

Phase:

PHASE1

PHASE2

Brief Summary

The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.

Detailed Description

In adults, drug clearance is less than half of the glomerular filtration rate and the drug half-life is 6-8 hours. Renal function in infants at birth is characterized by immature glomerular filtration...

Eligibility Criteria

Inclusion

  • Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with seizures.
  • Term infants (gestational age greater than or equal to 37 weeks.
  • \> 2500 grams (max blood for study 6mL =3%).
  • Postnatal age 14 days or less.
  • Serum creatinine less than 1.2 at time of enrollment.
  • Received loading dose of phenobarbital 20mg/kg.
  • Are still experiencing either clinical or electroencephalographic seizures despite this therapy.
  • For whom parental consent to participate in the study is obtained.

Exclusion

  • Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in seizure cessation.
  • Severe hypoxic ischemic injury likely to result in imminent death
  • The only significant exclusions that will be made in recruitment and enrollment will be the exclusion of infants who are judged by the attending neonatologist to be so critically ill that death is imminent and benefit from neonatal intensive care is very unlikely.
  • No rule-based criteria, (using lab or clinical parameters) adequately capture the complete nature of this clinical assessment.
  • In general any child receiving active treatment with head cooling will not be excluded.
  • Mechanical ventilation and/or the use of inotropic agents to support blood pressure will not be exclusion criteria.

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2011

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT00884052

Start Date

April 1 2007

End Date

October 1 2011

Last Update

March 26 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU)

San Diego, California, United States, 92103

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures | DecenTrialz